BAM
NBIX icon

Belpointe Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Belpointe Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,485
Closed -$1.35M – 1151
2025
Q4 		$1.35M Buy
+9,485
New +$1.37M 0.05% 332
2025
Q1 		– Sell
-8,852
Closed -$1.12M – 998
2024
Q4 		$1.12M Buy
+8,852
New +$1.09M 0.07% 280
2024
Q3 		– Sell
-8,113
Closed -$1.12M – 970
2024
Q2 		$1.12M Buy
8,113
+3,877
+92% +$532K 0.08% 243
2024
Q1 		$584K Buy
+4,236
New +$579K 0.04% 400
2023
Q2 		– Sell
-756
Closed -$76.5K – 2324
2023
Q1 		$76.5K Buy
756
+267
+55% +$27.8K ﹤0.01% 1463
2022
Q4 		$58.4K Buy
+489
New +$57.3K ﹤0.01% 1511

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belpointe Asset Management's NBIX Position: Q1 2026 in Review

Belpointe Asset Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 9,485 shares — an estimated $1.35M sold.

Belpointe Asset Management first reported a position in NBIX in Q4 2022 and held it in 6 quarters. The position peaked at $1.35M in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Belpointe Asset Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Belpointe Asset Management sold 9,485 Neurocrine Biosciences shares in Q1 2026, an estimated $1.35M.
  • Belpointe Asset Management first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 6 quarters.
  • Belpointe Asset Management's Neurocrine Biosciences position peaked at $1.35M in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Belpointe Asset Management's 13F filing for Q1 2026, filed 28 Apr 2026.